A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Conditions
- Diabetes
- Diabetes Mellitus, Type 1
Interventions
- DRUG: Faster-acting insulin aspart
- DRUG: insulin aspart
Sponsor
Novo Nordisk A/S